This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEC9H0KH_M.jpg
Investing.com – Johnson & Johnson (NYSE:JNJ) on Tuesday raised its guidance for both sales and earnings per share after reporting healthy growth in its medical devices and pharmaceutical businesses.
The company also saw the first $100 million in revenue from its Covid-19 shots.
J&J shares were down 0.4% in premarket, weighed by the concerns surrounding its Covid-19 vaccine, whose sales remain suspended after some cases of rare blood clotting were reported a few days ago.
The company increased its 2021 full-year guidance for adjusted operational sales growth to 9.3% and adjusted operational EPS growth to 16.8% at the midpoint.
In the forecast given on January 26, operational sales growth was seen to be 8.8% and adjusted operational EPS growth was expected to come at 16.4% in 2021.
The company reported first quarter sales of $22.32 billion, the 7.9% growth driven by 9.6% sales growth in the pharmaceutical segment and 10.9% jump in medical devices business.
Adjusted first quarter EPS of $2.59 increased 12.6% from a year earlier.
